AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00989768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A (Dysport®)
Description: Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2,5:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 5 units will be injected in the left or right forehead side.
Study NCT00989768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A/Botox®
Description: 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)
Study NCT00989768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A/Dysport®
Description: Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 4 units will be injected in the left or right forehead side, 2:1 ratio Dysport/Botox.
Study NCT00146575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (Cypher)
Description: patients have been implanted a Cypher stent
Study NCT00146575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (Taxus)
Description: patients have been implanted a Taxus stent
Study NCT02192502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human albumin 5%
Study NCT02192502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (Voluven)
Study NCT01196338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early weight-bearing and range of motion exercises
Description: * 0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~* At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed placed in orthosis, with instructions to be weightbearing as tolerated. Instructions for limited range of motion to be given;~* At 2 weeks to 6 weeks: Weightbearing as tolerated in orthosis, follow range of motion instructions;~* After 6 weeks: Instructions to continue weightbearing as tolerated, wean from orthosis.
Study NCT01196338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-weight bearing, no range of motion
Description: * 0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~* At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed, BK fibreglass cast or other orthosis applied, with instructions to continue non-weightbearing;~* At 2 weeks to 6 weeks: Ankle remains immobile and non-weightbearing;~* After 6 weeks: Begin weightbearing as tolerated. Instructions for limited range of motion to be given, and wean from orthosis.
Study NCT03550092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstract Semantic Association Network Training (AbSANT)
Description: In each session, the participant will be asked to categorize words, choose/discuss semantic features for each word that accurately describe the word, and generate as many words as possible within a category.
Study NCT00471081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One or 2 intramuscular injections.
Study NCT01863199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis (Treat and extend)
Description: Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
Study NCT01863199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis every 4 weeks
Description: Lucentis 0.5mg administered intravitreally every four weeks for 12 months
Study NCT01863199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis every 12 weeks
Description: Lucentis 0.5mg administered intravitreally every twelve weeks for 12 months
Study NCT05724680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive behavior therapy
Description: Psycho-therapeutic intervention
Study NCT03441750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin tablets will be administrated in the experimental arm.
Study NCT03441750 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard lifestyle intervention
Description: Standard lifestyle advice will be united for all subjects by providing special booklet.~* All participants will receive 20-30 minutes individual or group session with assigned nurse addressing the harm of prediabetes and the importance of a healthy lifestyle for preventing Diabetes.~* The amount of energy intake of the participants will be calculated based on the ideal body weight and physical activity levels. The sample recipe will be explained by the nurse and provided in the diet instruction.~* Moderate intensity physical activity (150 minutes per week) is recommended.~* Smoking cessation is encouraged for the smoker.~* Excessive alcohol intake is encouraged to avoid.
Study NCT00705042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Study NCT05724680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cognitive behavior therapy
Description: Psycho-therapeutic intervention
Study NCT02906501 — intervention group
Intervention type: PROCEDURE
Intervention: The Penn Web-Based Computerized Neurocognitive Battery
Description: The Battery (PennCNP) of the Brain Behavior Laboratory at the University of Pennsylvania offers a range of probes of human neuropsychological functioning . It was designed for neuropsychological measurement of major cognitive domains. The WebCNP is administered using clickable icons on desktop or laptop computers, in a fixed order. Administrating the tests in a standard fashion fostering optimal performance without aiding the participant is required. For each domain, accuracy and speed are computed. Full battery completion takes approximately 2 hours. Each test begins with a practice module, to assure understanding of the instructions.
Study NCT03054792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Oxygen Level Dependent [BOLD] MRI
Description: BOLD is a non-invasive T2\*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.
Study NCT03054792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diffusion-Weighted [DW] MRI
Description: DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells
Study NCT03054792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopy [MRS]
Description: MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue
Study NCT01270347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-376 (Levofloxacin Solution for Inhalation)
Description: MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment
Study NCT01270347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIS (Tobramycin Inhalation Solution)
Description: Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
Study NCT03238027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)
Study NCT03238027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (MEDI4736) is a humanized IgG1 kappa mAb that blocks the interaction of PD-L1 with PD-1 CD80 (B7.1) molecules
Study NCT02906501 — intervention group
Intervention type: PROCEDURE
Intervention: The Iowa Gambling Test (IGT)
Description: The essential feature of this task is that it mimics real-life situations in the way it factors uncertainty, reward and punishment. The task involves four decks of cards, named A, B, C and D. The goal is to maximize profit on a loan of play money. Subjects are required to make a series of 100 card selections, but are not told ahead of time how many card selections they are going to be allowed to make. Cards can be selected one at a time, from any deck, and subjects are free to switch from any deck to another, at any time and as often as they wish. The decision to select from one deck or another is largely influenced by schedules of reward and punishment. These schedules are pre-programmed and known to the examiner, but not to the subject (Bechara et al., 1994, 1999a).
Study NCT00481429 — intervention group
Intervention type: DRUG
Intervention: Rosiglitazone
Description: Rosiglitazone 4mg od, increased to 4mg bg at 4 weeks if HbA1C above 7%.
Study NCT03681158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium valproate
Description: Pharmaceutical form:Powder for oral solution reconstituted with water Route of administration: Oral
Study NCT03543930 — intervention group
Intervention type: DEVICE
Intervention: Postoperative preventive CPAP
Description: Administration of a course of 2 hours of CPAP with 7.5 cmH2O pressure and 0.30 FIO2
Study NCT01839110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.
Study NCT01839110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth twice per day for a total of 26 weeks.
Study NCT00233077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Assistance
Description: Patients will be surveyed to assess their knowledge about cancer \& its treatment, experience with \& access to health care system, trust, depression, social support \& self-efficacy. A Brief Screening Needs Assessment will be done to ascertain practical, informational or psychosocial needs; based on their responses, an individualized action plan to connect with patient assistance programs will be created for the intervention group. We will ask intervention patients if they connected with any programs in their action plan. For those who didn't connect, we will give their name to an outreach worker. The outreach worker will call patients and identify reasons for not contacting the assistance programs.
Study NCT00233077 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information only
Description: Control patients will be sent a pamphlet about breast cancer \& its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
Study NCT02635880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Enlighten Device
Description: Up to 3 laser treatments, spaced 4 to 6 weeks apart
Study NCT02145546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: Amiodarone: 200mg three times a day for two weeks, then change to 200mg per day for the rest of the study.
Study NCT02145546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propafenone
Description: 150mg per 8 hours, 3 times per day
Study NCT02145546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotalol
Description: 80mg twice per day.
Study NCT01505023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Partial meal replacement
Description: The PMR was designed to contain sufficient amounts of all vitamins and minerals. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
Study NCT01505023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partial meal replacement with inulin
Description: The PMR was designed to contain sufficient amounts of all vitamins and minerals plus inulin. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
Study NCT01505023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Women were asked to consume one 5g serving of inulin mixed with any drink at breakfast and same amount at dinner (10 g of inulin/d).
Study NCT03845153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Retard 850 mg
Description: tablet
Study NCT03845153 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet
Study NCT02765412 — intervention group
Intervention type: OTHER
Intervention: Webinar, Promotion, and Tool Access
Description: All sites will receive a professionally developed, 15-minute webinar that describes the tool's development (e.g., how the algorithm was designed) and a tutorial on how to use the web-site. The investigators will promote the webinar and using the tool through key local leaders. A web-link to use the tool will be placed within the lung cancer screening clinical reminder.
Study NCT04026074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Weight adapted drug application
Study NCT04026074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Weight adapted drug application
Study NCT04026074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Weight adapted drug application
Study NCT04026074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA Cream
Description: Salve application on the body part where the regional anaesthesia will be administered
Study NCT04026074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo iv
Description: i.v. administration of 0,9% NaCl
Study NCT04026074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo iv
Description: i.v. administration of 0,9% NaCl
Study NCT04026074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo salve
Description: Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
Study NCT02765412 — intervention group
Intervention type: OTHER
Intervention: LEAP
Description: Sites randomized to intensive implementation will be offered participation in the LEAP program. LEAP (Learn. Engage. Act. Program) is a multi-week, online learning collaborative using systems redesign techniques to help sites identify and overcome barriers to implementation of shared decision making (use of the Decision Precision tool).
Study NCT02765412 — intervention group
Intervention type: OTHER
Intervention: Audit and Feedback
Description: Providers at all sites will have access to this system. It will provide feedback on the screening and shared decision making process (e.g., number of provider's eligible patients screened for lung cancer, use of the tool, patient knowledge and satisfaction from patient surveys).
Study NCT02765412 — intervention group
Intervention type: OTHER
Intervention: Academic Detailing
Description: All sites will be offered an academic detailing approach to implementation of Lung Decision Precision. A trained detailer will travel to all sites who agree to a visit. The detailer will meet with individual primary care providers whenever possible, and groups of providers as necessary. He will present evidence for a risk-based approach to screening and how to use the tool with patients to make tailored screening recommendations.
Study NCT03239119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rE-4 5 mcg
Description: Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 5 mcg for 26 weeks - All are subcutaneously injected twice daily
Study NCT03239119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rE-4 10 mcg
Description: Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 10 mcg for 26 weeks - All are subcutaneously injected twice daily
Study NCT03239119 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 5 mcg
Description: Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 5 mcg for 26 weeks - All are subcutaneously injected twice daily
Study NCT03239119 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 10 mcg
Description: Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 10 mcg for 26 weeks - All are subcutaneously injected twice daily
Study NCT02184793 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EMD (Inclinomax)
Description: EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on
Study NCT04171466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin + Metronidazole
Description: Participants will be instructed to take 1 capsule of Ciprofloxacin (500mg) twice daily for 7 days and 1 capsule of Metronidazole (500mg) thrice daily for 7 days. Antibiotics should be taken at least 2 hours before or 6 hours after mineral supplements containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc.
Study NCT04171466 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin + Metronidazole
Description: Participants will be instructed to take 1 capsule of Ciprofloxacin (500mg) twice daily for 7 days and 1 capsule of Metronidazole (500mg) thrice daily for 7 days. Antibiotics should be taken at least 2 hours before or 6 hours after mineral supplements containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc.
Study NCT04171466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SH-DS01
Description: SH-DS01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.
Study NCT04171466 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules for SH-DS01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.
Study NCT01039701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: capsules, oral, 3 times daily
Study NCT01039701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, oral, 3 times daily, 4 weeks
Study NCT01859481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
Study NCT01859481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan HBr 40 mg
Description: All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
Study NCT01859481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan HBr 80 mg
Description: All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
Study NCT00003298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin was administered as part of the neoadjuvant regimen. It was given at a dose of 75 mg/m² via IV over approximately one hour, on day 1 of each cycle. Three cycles were given.
Study NCT00003298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Postoperative regimen 5-FU, along with Leucovorin, was given by IV bolus, with 5-FU given immediately after the Leucovorin
Study NCT00003298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Both 5-FU and Leucovorin will be given via IV bolus, with Leucovorin given immediately before 5-FU.
Study NCT00003298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel was administered as part of the neoadjuvant regimen. It was given at a dose of 175 mg/m² as a 3 hour continuous intravenous infusion on day 1. Three cycles were given.
Study NCT00003298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: The surgical procedure performed involved a radical subtotal or total gastrectomy.~A complete surgical resection was required
Study NCT00003298 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Concomitant chemotherapy and radiation therapy course: 5-FU 400 mg/m²/day + Leucovorin 20 mg/m²/day on days 1-4 of week one and days 1-3 of week 5 of XRT. Combined chemotherapy and radiation therapy were to begin 4 weeks after day 1 of the initial course of chemotherapy
Study NCT00514735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medtronic Cardiac Ablation System
Description: Arm 1 (Ablation Management): Ablation procedures using investigational catheters in left atrium. Cardioversion could be used to restore sinus rhythm if needed.